[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Omeros Corp (OMER)

Omeros Corp (OMER)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 958,391
  • Shares Outstanding, K 72,168
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,350 K
  • EBIT $ -123 M
  • EBITDA $ -123 M
  • 60-Month Beta 2.66
  • Price/Sales 96.01
  • Price/Cash Flow 7.89
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 74.18% (+0.46%)
  • Historical Volatility 51.59%
  • IV Percentile 14%
  • IV Rank 6.14%
  • IV High 355.15% on 05/16/25
  • IV Low 55.81% on 02/13/26
  • Expected Move (DTE 34) 2.00 (15.63%)
  • Put/Call Vol Ratio 0.83
  • Today's Volume 44
  • Volume Avg (30-Day) 2,130
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 60,278
  • Open Int (30-Day) 50,314
  • Expected Range 10.78 to 14.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.39
  • Number of Estimates 1
  • High Estimate $-0.39
  • Low Estimate $-0.39
  • Prior Year $-0.53
  • Growth Rate Est. (year over year) +26.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.09 +6.08%
on 04/16/26
15.32 -16.29%
on 05/01/26
+0.57 (+4.69%)
since 04/15/26
3-Month
9.77 +31.27%
on 03/30/26
15.32 -16.29%
on 05/01/26
+1.14 (+9.71%)
since 02/13/26
52-Week
2.95 +334.75%
on 07/01/25
17.65 -27.34%
on 12/24/25
+8.88 (+224.68%)
since 05/15/25

Most Recent Stories

More News
Omeros Q1 Earnings Call Highlights

Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem...

OMER : 12.81 (-3.54%)
Omeros Corporation Reports First Quarter 2026 Financial Results

– Conference Call Today at 4:30 p.m. ET

OMER : 12.81 (-3.54%)
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the first quarter 2026 on Wednesday, May 13, 2026 after market close. Omeros management will host a conference...

OMER : 12.81 (-3.54%)
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 7.23 (-1.90%)
OMER : 12.81 (-3.54%)
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

– Permanent, product-specific J-code facilitates efficient claims and reimbursement –

OMER : 12.81 (-3.54%)
Omeros: Q4 Earnings Snapshot

Omeros: Q4 Earnings Snapshot

OMER : 12.81 (-3.54%)
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

– Conference Call Today at 4:30 p.m. ET

OMER : 12.81 (-3.54%)
Omeros Burns Cash While Everyone Waits for YARTEMLEA's Story

Barchart Research What to Expect from OMER Earnings OMER Generated March 30, 2026 Current Price $9.81 EPS Estimate $-0.55 Consensus Rating Moderate Buy Average Move 18.93% Omeros Burns Cash While Everyone...

OMER : 12.81 (-3.54%)
Omeros Has Been Quietly Burning Through Cash. This Week, the Story Either Changes or It Doesn't.

Barchart Research What to Expect from OMER Earnings OMER Generated March 27, 2026 Current Price $9.88 EPS Estimate $-0.55 Consensus Rating Moderate Buy Average Move 18.93% Omeros Has Been Quietly Burning...

OMER : 12.81 (-3.54%)

Business Summary

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM)...

See More

Key Turning Points

3rd Resistance Point 16.71
2nd Resistance Point 15.71
1st Resistance Point 14.50
Last Price 12.81
1st Support Level 12.29
2nd Support Level 11.29
3rd Support Level 10.08

See More

52-Week High 17.65
Last Price 12.81
Fibonacci 61.8% 12.03
Fibonacci 50% 10.30
Fibonacci 38.2% 8.57
52-Week Low 2.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.